Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A drug originally developed for spinal cord injuries may be repurposed to fight Alzheimer's disease. Scientists at King's College London found that KCL-286 repairs DNA damage and reduces brain inflammation in mice — two processes that kick in early in the disease. Best part? It's already cleared Phase 1 human safety trials, potentially fast-tracking its path to clinical testing.
Scientists at King's College London have identified a promising new Alzheimer's drug candidate — and it's got a head start. KCL-286, originally developed for spinal cord injuries, has shown the ability to repair DNA damage and reduce brain inflammation in a mouse model of Alzheimer's disease. Unlike most treatments that zero in on amyloid-beta or tau protein buildup, this drug targets multiple harmful processes that can emerge early in the disease's progression.
What makes KCL-286 especially notable is its mechanism: it activates a protein in the retinoic acid (vitamin A) pathway, which plays a role in gene regulation and nervous system function. Earlier research linked disruptions in this pathway to amyloid-beta deposits in the brain. The drug also promotes repair of DNA double-strand breaks — a particularly dangerous form of genetic damage that can threaten cell survival if left unaddressed.
Key Takeaways:
Why it matters: Alzheimer's affects millions worldwide and current treatments offer only modest benefits. A drug that tackles multiple disease mechanisms simultaneously — and already has a safety track record in humans — could represent a meaningful step forward in the search for a true disease-modifying therapy.
